Analyst Christian Glennie of Stifel Nicolaus maintained a Buy rating on Genus plc (GNS – Research Report), retaining the price target of p2,940.00.
Christian Glennie’s rating is based on the positive trajectory Genus plc is experiencing across various regions and sectors. The company’s trading update indicates that they are on track with market expectations, showing a promising growth in adjusted profit before tax for the fiscal year 2025. Notably, the strong performance of PIC in North America and Latin America, coupled with stable results in Europe despite challenging comparisons, highlights the company’s resilience and effective regional strategies.
Furthermore, the ABS segment has shown recovery growth, benefiting from successful cost-saving initiatives and improved trading conditions. The progression of their PRRS Resistant Pig program, with significant regulatory submissions, underscores potential future advancements and revenue opportunities. These factors, combined with the company’s strategic execution and robust market positioning, form the basis for the Buy rating recommendation.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Genus plc (GNS) Company Description:
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. The company generates most of its revenue from its porcine exposure, followed by its bovine exposure. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company’s primary product is bull semen, which is delivered through artificial insemination to improve its customers’ herds and their efficiency.
